Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4KTA9
|
|||
| Drug Name |
INCAGN2385
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | |
| Company |
Agenis; Incyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation gene 3 protein (LAG3) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04370704) Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Agenus. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.